Oncobiologics Inc.

Oncobiologics Inc. company information, Employees & Contact Information

OVERVIEW Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company. We have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our BioSymphony™ Platform. Oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mAb biosimilars and was designed to provide significant pricing flexibility. PIPELINE Oncobiologics is currently developing a portfolio of eight commercially attractive mAb biosimilars. The company’s most advanced assets, ONS-3010 (a biosimilar of Humira®) and ONS-1045 (a biosimilar of Avastin®) have both successfully completed Phase I trials. We have initiated Phase 3 preparatory activities for ONS-3010 and ONS-1045.` STRATEGY Oncobiologics utilizes its BioSymphony Platform to develop, manufacture and commercialize technically challenging, cost-effective biosimilars on an accelerated timeline and to offer contract development and manufacturing services to development stage biologics companies.

Company Details

Employees
15
Founded
-
Address
7 Clarke Drive, Cranbury,new Jersey 08512,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cranbury, New Jersey
Looking for a particular Oncobiologics Inc. employee's phone or email?

Oncobiologics Inc. Questions

News

Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire

Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference GlobeNewswire

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - GlobeNewswire

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) GlobeNewswire

Biosimilars of denosumab - Generics and Biosimilars Initiative

Biosimilars of denosumab Generics and Biosimilars Initiative

Investments and Management Moves - communitynews.org

Investments and Management Moves communitynews.org

Outlook Therapeutics Provides Update on Type A Meeting with FDA - GlobeNewswire

Outlook Therapeutics Provides Update on Type A Meeting with FDA GlobeNewswire

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewswire

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering GlobeNewswire

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants - GlobeNewswire

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire

Outlook Therapeutics Announces Completion of Warrant Restructuring - GlobeNewswire

Outlook Therapeutics Announces Completion of Warrant Restructuring GlobeNewswire

Outlook Therapeutics Receives FDA Agreement for Three - GlobeNewswire

Outlook Therapeutics Receives FDA Agreement for Three GlobeNewswire

Top Oncobiologics Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant